17,049 Shares in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Purchased by Illumine Investment Management LLC

Illumine Investment Management LLC bought a new stake in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund bought 17,049 shares of the company's stock, valued at approximately $633,000.

Several other institutional investors and hedge funds have also bought and sold shares of AMPH. Pacer Advisors Inc. lifted its holdings in shares of Amphastar Pharmaceuticals by 51,977.4% in the 4th quarter. Pacer Advisors Inc. now owns 1,350,368 shares of the company's stock worth $50,139,000 after purchasing an additional 1,347,775 shares in the last quarter. Boston Trust Walden Corp lifted its stake in shares of Amphastar Pharmaceuticals by 81.4% in the fourth quarter. Boston Trust Walden Corp now owns 978,920 shares of the company's stock valued at $36,347,000 after buying an additional 439,281 shares in the last quarter. Hotchkis & Wiley Capital Management LLC bought a new stake in shares of Amphastar Pharmaceuticals during the third quarter worth about $10,804,000. Portolan Capital Management LLC raised its holdings in shares of Amphastar Pharmaceuticals by 201.1% in the 3rd quarter. Portolan Capital Management LLC now owns 327,764 shares of the company's stock worth $15,906,000 after acquiring an additional 218,901 shares during the last quarter. Finally, Weiss Asset Management LP bought a new position in Amphastar Pharmaceuticals in the 3rd quarter valued at about $4,967,000. 65.09% of the stock is owned by institutional investors.

Insider Activity at Amphastar Pharmaceuticals

In other Amphastar Pharmaceuticals news, EVP Rong Zhou sold 7,000 shares of the business's stock in a transaction on Thursday, December 12th. The stock was sold at an average price of $44.42, for a total value of $310,940.00. Following the sale, the executive vice president now directly owns 118,469 shares in the company, valued at $5,262,392.98. The trade was a 5.58 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Richard K. Prins sold 10,000 shares of Amphastar Pharmaceuticals stock in a transaction dated Monday, December 9th. The stock was sold at an average price of $43.77, for a total value of $437,700.00. Following the completion of the sale, the director now directly owns 30,471 shares of the company's stock, valued at approximately $1,333,715.67. This trade represents a 24.71 % decrease in their position. The disclosure for this sale can be found here. 27.10% of the stock is owned by company insiders.

Remove Ads

Amphastar Pharmaceuticals Stock Up 0.4 %

NASDAQ:AMPH traded up $0.10 on Tuesday, hitting $27.62. The stock had a trading volume of 803,113 shares, compared to its average volume of 585,969. Amphastar Pharmaceuticals, Inc. has a 1 year low of $26.98 and a 1 year high of $53.96. The firm's fifty day simple moving average is $34.50 and its two-hundred day simple moving average is $42.44. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.61 and a current ratio of 3.43. The stock has a market cap of $1.33 billion, a P/E ratio of 9.21, a price-to-earnings-growth ratio of 2.19 and a beta of 0.81.

Wall Street Analyst Weigh In

AMPH has been the subject of a number of recent research reports. Piper Sandler lowered Amphastar Pharmaceuticals from an "overweight" rating to a "neutral" rating and decreased their price objective for the stock from $66.00 to $36.00 in a report on Tuesday, February 4th. Wells Fargo & Company initiated coverage on Amphastar Pharmaceuticals in a research report on Friday, November 22nd. They set an "equal weight" rating and a $55.00 target price on the stock. Four equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Hold" and a consensus target price of $50.33.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.